The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
BIOMARIN PHARMACEUTICAL INC COM 09061G101 19,200 182,300 SH   SOLE   182,300 0 0
HERON THERAPEUTICS INC COM 427746102 118,768 4,867,530 SH   SOLE   4,867,530 0 0
HERON THERAPEUTICS INC COM 427746102 7,889 323,307 SH   OTR 1 0 323,307 0
LA JOLLA PHARMACEUTICAL CO COM 503459604 79,816 2,872,130 SH   SOLE   2,872,130 0 0
LA JOLLA PHARMACEUTICAL CO COM 503459604 1,191 42,840 SH   OTR 1 0 42,840 0
MERRIMACK PHARMACEUTICALS INC NOTE 4.5% 7/15/20 590328AA8 5,259 3,500,000 PRN   SOLE   3,500,000 0 0
OPKO HEALTH INC COM 68375N103 20,815 2,475,000 SH   SOLE   2,475,000 0 0
OPKO HEALTH INC DEBT 3.0% 2/1/33 68375NAB9 18,247 14,000,000 PRN   SOLE   14,000,000 0 0